Caso 28.2015

The n e w e ng l a n d j o u r na l of m e dic i n e
Case Records of the Massachusetts General Hospital
Founded by Richard C. Cabot

Eric S. Rosenberg, M.D., Editor Nancy Lee Harris, M.D., Editor
Jo‑Anne O. Shepard, M.D., Associate Editor Alice M. Cort, M.D., Associate Editor
Sally H. Ebeling, Assistant Editor Emily K. McDonald, Assistant Editor
Case 28-2015: A 32-Year-Old Man

with Fever, Headache, and Myalgias
after Traveling from Liberia
Paul D. Biddinger, M.D., David C. Hooper, M.D., Erica S. Shenoy, M.D., Ph.D.,
Ednan K. Bajwa, M.D., M.P.H., Gregory K. Robbins, M.D., M.P.H.,
and John A. Branda, M.D.
Pr e sen tat ion of C a se

From the Departments of Emergency Dr. Paul D. Biddinger: In December 2014, the emergency department of this hospital
Medicine (P.D.B.), Infectious Diseases
received a call from a public health authority about a 32-year-old man with fever,
(D.C.H., E.S.S., G.K.R.), Pulmonary and
Critical Care (E.K.B.), and Pathology headache, and myalgias that had developed 8 days after he had traveled from Liberia.
(J.A.B.) and the Infection Control Unit The patient had been in Liberia for 3 months, working as an administrator for
(D.C.H., E.S.S.), Massachusetts General
a nonprofit organization that was involved in the response to the epidemic of
Hospital; and the Departments of Emer‑
gency Medicine (P.D.B.), Medicine (D.C.H., Ebola virus disease (EVD). He had not had any known direct contact with persons
E.S.S., E.K.B., G.K.R.), and Pathology infected with the virus. While he was in Liberia, he did observe patients with EVD,
(J.A.B.), Harvard Medical School — both
as well as health care workers and funeral personnel in protective clothing, but
in Boston.
only from afar. He departed from Liberia 8 days before admission. He arrived in
N Engl J Med 2015;373:1060-7.
the United States the day after he left Liberia and immediately began participating
DOI: 10.1056/NEJMcpc1503828
Copyright © 2015 Massachusetts Medical Society. in an EVD monitoring program administered by a public health authority, with
plans to participate in the program for the 21-day period after his departure from
Liberia. As part of this program, the patient measured his temperature twice
daily, performed self-observation for other signs or symptoms of infection, and
communicated each day with a public health official about his condition. He re-
ported temperatures that were within normal limits and had felt well until the
morning of the day of admission, when a headache and myalgias developed. Sev-
eral hours later, his temperature rose to 39.3°C, with associated chills. The patient
contacted the public health authority, who subsequently called the person who had
been previously specified as the point of contact at this hospital to discuss the
facts of the case and to notify the hospital about the patient’s impending arrival.
The public health authority coordinated the dispatch of emergency medical services
(EMS) to the patient’s home.
EMS personnel performed an initial interview and assessment of the patient
while maintaining a distance of greater than 6 ft (2 m) between themselves and
the patient. The patient appeared to be alert, oriented, conversant, ambulatory, and
well. He was provided with an impermeable jumpsuit and a face mask; EMS per-
1060 n engl j med 373;11 nejm.org September 10, 2015
The New England Journal of Medicine

Downloaded from nejm.org by Isabel Garcia on August 26, 2017. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.
Case Records of the Massachuset ts Gener al Hospital
sonnel also put on personal protective equip- department, the patient reported having increas-
ment (PPE) and draped the patient compartment ing chills and feeling more tired; he had slight
of the ambulance in plastic. The patient was then diaphoresis, and the temperature was 39.7°C.
transported to the emergency department of this Acetaminophen was administered.
hospital for further evaluation. Management decisions were made, and a di-
On arrival at the emergency department, the agnostic test was performed.
patient was immediately placed in a negative-
pressure isolation room. He rated his headache Assessing Risk for EVD
at 7 or 8 on a scale of 0 to 10 (with 10 indicating Dr. David C. Hooper: The establishment of case
the most severe pain) and reported fatigue, mild definitions by public health authorities ensures
nausea, and a reduced appetite. He had a history consistency and appropriateness of screening for,
of a mandibular fracture that had occurred in a identification of, and response to EVD. On the
sledding accident 6 years previously, and he had basis of a combination of symptoms and epide-
undergone strabismus repair in early childhood miologic risk, this patient was considered to be
and laser-assisted in situ keratomileusis 1 year a “person under investigation” (PUI) for EVD by
before admission. He also had a history of trau- the Centers for Disease Control and Prevention
matic microhyphema and partial-thickness cor- (CDC). At the time the patient presented to this
neal laceration that had occurred after he was hospital, criteria for the status of a person under
bitten on the face by a dog 6 years earlier, at investigation for EVD included the presence of
which time the rabies vaccine and rabies immune either a fever (documented or subjective) or one
globulin were administered. Before the patient or more of the following symptoms: severe head-
traveled to Liberia, he had received the tetanus– ache, muscle pain, vomiting, diarrhea, abdomi-
diphtheria–acellular pertussis vaccine, the live- nal pain, or unexplained hemorrhage. Fever,
attenuated oral typhoid vaccine, and the yellow headache, and myalgia were present in this pa-
fever vaccine. He had received doxycycline for tient. Because such symptoms are nonspecific,
malaria prophylaxis during the trip, but he dis- persons under investigation for EVD must also
continued taking the medication on the day he have epidemiologic risk factors — which are
returned to the United States. He took no other stratified into risk categories of high, some, and
medications and had no known allergies. low (but not zero) (Table 1)1 — with exposures
The patient was single; he had recently ended occurring within the past 21 days, which is the
a long-term monogamous relationship and had longest known incubation period for Ebola virus.
no new sexual partners. He lived with room- Although this patient had had no known expo-
mates, consumed alcohol in moderation, and did sure to EVD, he was considered to be in the low
not smoke or use illicit drugs. During the previ- (but not zero) risk category because he had spent
ous 9.5 years, he had traveled extensively in sub- time in Liberia, one of the countries (along with
Saharan Africa, the Middle East, and the Cauca- Sierra Leone and Guinea) in which widespread
sus. During his trip to Liberia, he had spent half transmission of Ebola virus had occurred during
his time in Monrovia and the remainder divided the period of his visit. Because this patient was
between two sites where there were no known considered to be a person under investigation for
active cases of EVD. He had not used public EVD, he was transported to this hospital, and
transportation, shared his sleeping quarters with the hospital’s Biothreat Care Unit was activated.
other persons, or had exposure to animals; he
had been bitten by mosquitoes. Four days before Preparations and Activation of the Biothreat
admission, he had spent time with a friend who Care Unit
had a resolving upper respiratory tract infection. Dr. Erica S. Shenoy: In preparation for the possible
On limited examination, the patient did not need to care for a patient with suspected or con-
appear to have signs that were immediately worri- firmed EVD, the hospital’s Biothreat Care Unit,
some for possible sepsis. He was alert, coopera- a discrete physical space, had been created at the
tive, and oriented to person, place, and time. end of an existing medical intensive care unit
Extraocular-muscle movements were intact, oral (MICU) corridor, allowing for unidirectional
mucous membranes were dry, and respiratory ef- flow of the care team and for isolation of the
fort was normal. While he was in the emergency Biothreat Care Unit from the rest of the MICU.
n engl j med 373;11 nejm.org September 10, 2015 1061

Table 1. Epidemiologic Risk Factors for Ebola Virus Disease (EVD).*
Risk Category and Associated Risk Factors Present in This Patient

High
Percutaneous exposure (e.g., needle stick) or exposure of mucous membranes to No
blood or body fluids of a person with EVD while the person was symptomatic
Exposure — without wearing the appropriate PPE — to the blood or body fluids No
of a person with EVD while the person was symptomatic
Processing — without wearing the appropriate PPE or taking standard biosafety No
precautions — of the blood or body fluids of a person with EVD while the per‑
son was symptomatic
Direct contact — without wearing the appropriate PPE — with a dead body in a No
country with widespread transmission of Ebola virus
Residence in the immediate household and provision of direct care to a person No
with EVD while the person was symptomatic
Some
Direct contact — while wearing the appropriate PPE — with a person with EVD No
while the person was symptomatic and while in a country with widespread
transmission of Ebola virus
Close contact in households, health care facilities, or community settings with a No
person with EVD while the person was symptomatic†
Low (but not zero)
Residence in or visit to a country with widespread transmission of Ebola virus Yes
within the past 21 days and no known exposures
Brief direct contact (e.g., shaking hands) — without wearing the appropriate PPE No
— with a person with EVD while the person was in the early stage of disease
Brief proximity (i.e., being in the same room for a brief period of time) to a per‑ No
son with EVD while the person was symptomatic
Direct contact — while wearing the appropriate PPE — with a person with EVD No
while the person was symptomatic and while in a country without widespread
transmission of Ebola virus
Travel on an aircraft with a person with EVD while the person was symptomatic Unknown
* Data are from the Centers for Disease Control and Prevention.1 Body fluids include but are not limited to feces, saliva,
sweat, urine, vomit, and semen. PPE denotes personal protective equipment.
† Close contact is defined as being, for a prolonged period of time while not wearing the appropriate PPE, within approxi‑
mately 3 ft (1 m) of a person with EVD while the person was symptomatic.
On the patient’s admission, a site manager was 1 attending physician and 4 nurses per shift. The
designated from a pool of trained personnel to choice of PPE reflected a goal of no skin expo-
oversee the preparation of the unit, which in- sure, in accordance with CDC guidelines.2 Clini-
cluded relocating existing patients, removing cal and support staff who were required to have
unnecessary supplies and equipment from the proficiency in PPE for EVD had participated in
rooms, and stocking each room with materials small-group tutorials in which they were taught
specific for the care of a patient with suspected how to put on and remove PPE; a checklist was
EVD. The site manager was responsible for en- used in this process, with a staff member calling
suring the safe and effective delivery of the pa- out each step and observing the other members
tient’s treatment.2 for adherence to the protocol. Clinicians had also
The Biothreat Care Unit clinical care team previously practiced performing specific manual
was drawn from a group of 32 MICU nurses and medical tasks — including phlebotomy, specimen
16 attending physicians who had volunteered packaging and transport, and placement of intra-
months earlier to participate in PPE training, vascular catheters — while wearing PPE. Once
planning meetings, and both institution-wide the physical setup and staffing plan were in place
and unit-based drills. The staffing plan included and the staff of the Biothreat Care Unit agreed

that the unit was ready to accept this patient, an onset of fever, chills, sweats, malaise, headache,
attending physician and nurse donned PPE and nausea, and body aches was most consistent
transported him from the emergency department. with Plasmodium falciparum malaria; the patient
had reported receiving numerous mosquito bites
Initial Evaluation and Management while he was in Liberia, a country in which this
Dr. Ednan K. Bajwa: On the patient’s arrival in the vectorborne disease is endemic. Doxycycline had
Biothreat Care Unit, a second examination was been an appropriate choice for malaria chemo-
performed. The temperature was 38.5°C, the blood prophylaxis, but the patient had not recalled in-
pressure 155/91 mm Hg, the pulse 99 beats per structions to continue taking the medication for
minute, the respiratory rate 18 breaths per min- 28 days after leaving Liberia, and this regimen
ute, and the oxygen saturation 96% while he was had been terminated prematurely. His stay in
breathing ambient air. The patient appeared to Liberia had been 3 months in duration, and the
be flushed and diaphoretic but otherwise well. incubation period of malaria would have been
The neck was supple, the abdomen was soft and consistent with an onset of illness in this patient
nontender, and the neurologic examination was 8 days after he left the country.
normal. Auscultation was precluded by the hood The differential diagnosis also included other
of the clinician’s PPE. There was an erythematous causes of acute febrile illness, such as enteric
annular lesion (2 cm in diameter) with an over- fever, arboviral infections (e.g., dengue or chikun-
lying scale between the 4th and 5th toes of the gunya virus infection), influenza, leptospirosis,
left foot, without associated tenderness, edema, legionellosis, acute human immunodeficiency
or warmth. virus, and rickettsial infection.3,4 However, labo-
The patient was admitted to the hospital soon ratory testing was limited by the strict precau-
after the onset of his symptoms and was not tions taken with this patient and his blood and
critically ill. However, given the possible diagno- body-fluid specimens. He was at low risk for
sis of EVD, we carefully planned for the care that EVD, but coinfection with malaria has been re-
would be required if advancing disease were to ported in about 10% of patients with EVD. Be-
develop. Our management strategy was guided cause the patient was still within the 21-day in-
by experiences reported by EVD treatment cen- cubation period for Ebola virus and had met the
ters in the United States and Europe that had criteria for a person under investigation for EVD,
provided care for a moderate number of health the diagnosis could not be clinically ruled out on
care workers and other travelers returning from the basis of the history and physical examina-
West Africa. We were prepared to manage fluid tion alone. Therefore, we decided to test for
and electrolyte abnormalities aggressively and to malaria and EVD.
maintain adequate nutritional status in the pa-
tient, including through the delivery of paren- Cl inic a l Di agnosis
teral nutrition if enteral nutrition was no longer
possible owing to development of severe gastro- Plasmodium falciparum malaria.
intestinal symptoms. We were also prepared to
use mechanical ventilation and renal-replacement Pathol o gic a l Discussion
therapy, both of which have been initiated suc-
cessfully in patients with EVD in whom organ Dr. John A. Branda: In the months before this pa-
failure has developed. As part of the initial treat- tient’s admission, the clinical laboratories (in
ment of this patient, we asked the infectious consultation with hospital leaders in emergency
diseases consultation service for guidance re- medicine, critical care, and infectious diseases)
garding other possible causes of this patient’s developed a plan to offer needed laboratory test-
illness and suggesting appropriate empirical ing for a person under investigation for EVD that
antimicrobial therapy, if needed. would protect laboratory workers and minimize
disruptions to routine laboratory operations. The
goal was to limit testing to assays that were
Cl inic a l Impr e ssion
predicted to be essential for the care of a patient
Dr. Gregory K. Robbins: Although there was con- being evaluated for or with a diagnosis of EVD.
cern that this patient may have EVD, the abrupt Our plan required that all specimen manipula-

tion and analysis be performed in a certified was admitted, and within approximately 1 hour,
biosafety cabinet and without the use of sharp we were able to report to the clinical team that
needles or other devices that could puncture the he tested positive for a P. falciparum–specific an-
skin. This precluded the use of our main analyz- tigen in the blood (Fig. 1). Other values that were
ers and instruments, so we focused instead on obtained on admission are shown in Table 2.
point-of-care testing devices. We planned to per- Several hours after presentation, after safe pack-
form testing in the mycobacteriology laboratory aging and transport of blood specimens to the
because this area has a biosafety level of 2+, is state public health laboratory, a PCR assay for
under negative pressure, contains an appropriate Ebola virus was performed and was negative.
biosafety cabinet, and is relatively secluded, there-
by ensuring that foot traffic could be controlled Discussion of M a nagemen t
and that the testing would have a minimal effect
on routine laboratory operations. Dr. Robbins: Once the test for P. falciparum malaria
We had anticipated that a person under inves- was positive, therapy with artemether and lume-
tigation for EVD would be a febrile patient who fantrine was administered. Miconazole was ap-
had recently been in West Africa, and thus we plied topically for the treatment of tinea pedis;
thought that it would be essential to offer ma- other empirical antimicrobial agents were not
laria testing, as well as to obtain routine blood prescribed. Lactated Ringer’s solution, ibuprofen,
cultures to detect agents such as Salmonella typhi and enoxaparin were administered. The patient
and Neisseria meningitidis, which are endemic in felt better during his first night in the hospital,
that region. For blood cultures, we acquired a but the following morning, a temperature of
dedicated instrument for incubation and detec-
tion and planned to use plastic rather than glass
bottles to reduce the chance of breakage. In ad-
dition, we anticipated the need to measure elec-
trolyte levels and renal function in a patient with
vomiting and diarrhea, to measure the hemoglo-
bin level and hematocrit in a patient with hemor-
rhage or malaria, and to measure levels of blood
gases in a critically ill patient. We obtained a
handheld analyzer that could be used to perform
these tests on venous blood. Finally, we estab-
lished a procedure for prompt transport of speci-
mens to our state public health laboratory, where
a polymerase-chain-reaction (PCR) assay of the
blood for Ebola virus could be performed.
A small group of medical technologists was
Figure 1. Microbiologic Test Results.
trained on how to properly put on and remove
A rapid lateral-flow immunochromatographic assay for
the required PPE and to perform testing accord- the qualitative detection of plasmodium (malarial) an‑
ing to procedures clearly outlined on previously tigens in blood was performed. The appearance of a
developed checklists. A rotation was established pink-to-purple line at the C (positive control) position
to provide coverage by three technologists at all indicates valid performance of the assay, and the ap‑
pearance of the line at the T1 (test 1) position indi‑
times: one to perform testing, a second to focus
cates the presence of a histidine-rich protein II antigen
on the checklists, and a third to manage the specific to Plasmodium falciparum. No line was ob‑
transfer of specimens and supplies into and out served at the T2 (test 2) position; a line at this position
of the biosafety cabinet as needed. Two laboratory would have indicated the presence of an aldolase anti‑
directors were also included in the on-call team, gen that is commonly associated with multiple species
of human malarial parasites. The term mixed denotes
to determine an individualized testing strategy
mixed infection with P. falciparum and another plas‑
in consultation with the care teams and to man- modium species, Neg. no infection, P.f. infection with
age ongoing laboratory activities with minimal P. falciparum, P.m. infection with P. malariae, P.o. in‑
disruption. fection with P. ovale, and P.v. infection with P. vivax.
These plans were activated when this patient

Table 2. Laboratory Data.*
Reference Range, Second Hospital Third Hospital

Variable Adults† On Admission Day Day
Hematocrit (%) 41.0–53.0 42.0 47.0 40.0
Hemoglobin (g/dl) 12.0–16.0 14.3 16.0 13.6
Sodium (mmol/liter) 135–145 134 137 139
Potassium (mmol/liter) 3.4–4.8 3.5 3.7 3.6
Chloride (mmol/liter) 100–108 96 96 98
Carbon dioxide (mmol/liter) 23–32 24 25 26
Anion gap (mmol/liter) 10–20 19 21 19
Ionized calcium (mmol/liter) 1.14–1.30 1.13 1.17 1.18
Glucose (mg/dl) 70–110 103 104 94
Urea nitrogen (mg/dl) 8–25 11 11 4
Creatinine (mg/dl) 0.60–1.50 1.20 1.10 1.00
* To convert the values for ionized calcium to milligrams per deciliter, divide by 0.250. To convert the values for glucose
to millimoles per liter, multiply by 0.05551. To convert the values for urea nitrogen to millimoles per liter, multiply by
0.357. To convert the values for creatinine to micromoles per liter, multiply by 88.4.
† Reference values are affected by many variables, including the patient population and the laboratory methods used. The
ranges used at Massachusetts General Hospital are for adults who are not pregnant and do not have medical conditions
that could affect the results. They may therefore not be appropriate for all patients.
39.8°C developed; he reported diaphoresis and reported by another U.S. hospital highlighted
worsening headaches and myalgias. Additional the importance of considering the diagnosis of
laboratory test results are shown in Table 2. The EVD and planning a strategy to safely evaluate
patient’s fever abated on the third hospital day, the patient once this possibility is considered.6
and by the fourth hospital day, headaches and Prompt recognition of the possibility of EVD al-
myalgias had resolved; a decision was made to lows for early and aggressive care, which is impor-
forgo repeat PCR testing for Ebola virus. Isolation tant for survival.7 Furthermore, rapid isolation of
precautions were removed, and the patient was the patient and implementation of personal pro-
embraced by many members of the care team. tective measures decrease the chance of nosoco-
Dr. Biddinger: As the strategy for the care of mial transmission of disease. Second, a patient
this patient shows, an extensive amount of plan- such as this one, for whom EVD is included in
ning and other preparation is required for medi- the differential diagnosis, may also face the some-
cal providers, hospitals, and health systems to what unusual danger of a delay or failure in the
safely provide high-quality care for patients with recognition and treatment of alternative diagno-
suspected EVD or infection with another rare ses because of the limitations placed on labora-
but highly infectious pathogen. It is unlikely that tory testing, imaging studies, and other diagnos-
most clinicians in the United States will care for tic services for patients who require the highest
a patient with a confirmed diagnosis of EVD, but levels of isolation.8 At this hospital, the tests
with the ease of global travel, it is certainly pos- available under these circumstances allowed us
sible that many clinicians could encounter pa- to rapidly make a diagnosis of malaria and to
tients, such as this one, for whom the diagnosis initiate treatment.
of EVD is considered but an alternative diagnosis Finally, the development of procedures for ob-
is ultimately made. Despite this possibility, recent taining an appropriate travel history from pa-
research has shown that very few clinicians have tients who present with symptoms of emerging
felt adequately prepared to handle this scenario.5 infectious diseases will expedite early recogni-
We learned several lessons in our preparation tion. Websites that list diseases of concern, the
for and care of this patient. First, the recent ex- countries in which such diseases are active, and
perience of nosocomial transmission of EVD links to current case definitions — such as sites

maintained by the CDC, the Department of fection with a non–P. falciparum plasmodium spe-
Health and Human Services Office of the As- cies represented reactivation of a dormant infec-
sistant Secretary for Preparedness and Response, tion that had been acquired during an earlier trip
and other appropriate expert organizations — to Kenya; some reports suggest that treatment of
are important resources. The establishment of a P. falciparum may increase the risk of reactivation
robust plan for the management of suspected of P. vivax.12,13
cases, including provisions for patient transfer The patient is here today, and I would like to
to a specified safe location of care delivery, will ask him to say a few words about his experience.
benefit both the patient and the health care pro- The Patient: When I woke up feeling sick that
viders. morning, I knew rationally that it wasn’t Ebola.
Modifying a hospital’s physical plant to safely I had not had direct contact with anyone who
house a person who is under investigation for was symptomatic during my time in Liberia, so
EVD, as was done at this hospital, can be very I was at very low risk. But as the day progressed,
costly and may not be necessary for all hospi- and the number of resources at the disposal of
tals.9,10 The establishment of a rational, sustain- the state and hospital that were being used be-
able plan at each level of the health care system came apparent to me, I started to think, “Wow,
and of a network of institutions to which per- they are building an isolation unit for me, they
sons under investigation for EVD can be sent for are wearing space suits, and the media are inter-
evaluation and treatment will enhance the abil- ested. Maybe I do have Ebola.”
ity to safely consider the diagnosis of EVD while As that day went on, it was helpful that the
limiting risks to the public, medical providers, extra precautions and extraordinary circum-
and individual patients. stances were explained to me as they unfolded
and that Dr. Robbins called my mother before
the malaria test came back positive and talked
Fol l ow-up
her through the hysteria she was feeling. In gen-
Dr. Robbins: After discharge, the patient contin- eral, everyone who participated in my care pro-
ued to participate in the EVD monitoring pro- jected an effective bedside manner, even while
gram for the full 21-day period after his depar- they were wearing space suits, which was pretty
ture from Liberia; he did not have recrudescence remarkable.
of fever during that time. However, 6 weeks after Something that struck me as I was lying there
admission, he called to report that fevers, rigors, was the contrast between the deployment of re-
and headaches had recurred. He was seen in a sources here and what I had seen in Liberia.
clinic at this hospital, and diagnostic tests were There were only 50 doctors to serve Liberia before
performed. the outbreak, and of the more than 300 health
Dr. Branda: Repeat testing for malaria with the care workers who have died of Ebola in West
use of a rapid antigen-detection assay was nega- Africa, 180 have been in Liberia. All the factors
tive for the P. falciparum–specific antigen but was that made this experience as pleasant as possible
positive for a common plasmodium-specific an- for me — like getting to the hospital right away,
tigen. Examination of thick and thin peripheral- receiving a rapid diagnosis, and having great
blood smears revealed malarial parasites in ap- supportive care and reassurance — have been
proximately 0.1% of the red cells; these parasites lacking for so many people affected by this epi-
were morphologically incompatible with P. falci- demic in West Africa.
parum, but their species could not be determined One other thing that hasn’t yet been men-
with certainty. tioned is the lengths to which the hospital ad-
Dr. Robbins: A second course of artemether ministration went to protect my identity. I didn’t
and lumefantrine was administered, and prima- fully realize the importance of this at the time,
quine phosphate was prescribed to reduce the but in retrospect, it was really important.
risk of future relapses.11 Primaquine phosphate I’ve told a lot of people since my hospitaliza-
had not been given initially because the plasmo- tion that although I was stuck in the same room
dium species that creates latent hypnozoites is for 3 days, the experience was about as positive
uncommon in Liberia. It is possible that the in- as I could expect.

Fina l Di agnosis This case was presented at Emergency Medicine Grand

Rounds, hosted by Brigham and Women’s Hospital.
Disclosure forms provided by the authors are available with
Malaria due to Plasmodium falciparum and non– the full text of this article at NEJM.org.
P. falciparum plasmodium species.
References
1. Centers for Disease Control and Pre- 4. Ryan ET, Wilson ME, Kain KC. Illness 9. Hladky GB. Hospitals have spent
vention. Case definition for Ebola virus dis- after international travel. N Engl J Med $5 million to prepare for Ebola. Hartford
ease (EVD). 2015 (http://www.cdc.gov/vhf/ 2002;347:505-16. Courant. December 1, 2014.
ebola/healthcare-us/e valuating-patients/ 5. APIC Ebola readiness poll:results of 10. Firgir J. Ebola in the U.S.: who pays the
case-definition.html). an online poll of infection preventionists. bills? CBS News. October 31, 2014 (http://
2. Centers for Disease Control and Pre- Washington, DC:Association for Profes- www.cbsnews.com/news/ebola-in-the-us
vention. Guidance on personal protec- sionals in Infection Control and Epidemiol- -who-pays-the-bills).
tive equipment to be used by healthcare ogy, 2014 (http://www.apic.org/Resource_/ 11. Baird JK, Hoffman SL. Primaquine
workers during management of patients TinyMceFileManager/Topic-specific/Ebola therapy for malaria. Clin Infect Dis 2004;
with Ebola virus disease in U.S. hospi- _Readiness_Poll_Results_FINAL.pdf). 39:1336-45.
tals, including procedures for putting on 6. Weber EJ. A man walks into an ED . . . . 12. Douglas NM, Nosten F, Ashley EA, et al.
(donning) and removing (doffing). 2014 Emerg Med J 2014;31:950. Plasmodium vivax recurrence following fal-
(http://www.cdc.gov/vhf/ebola/healthcare 7. West TE, von Saint André-von Arnim A. ciparum and mixed species malaria: risk
-us/ppe/g uidance.html). Clinical presentation and management of factors and effect of antimalarial kinet-
3. Boggild AK, Esposito DH, Kozarsky severe Ebola virus disease. Ann Am Thorac ics. Clin Infect Dis 2011;52:612-20.
PE, et al. Differential diagnosis of illness Soc 2014;11:1341-50. 13. White NJ. Determinants of relapse
in travelers arriving from Sierra Leone, 8. Clinical inquiries regarding Ebola vi- periodicity in Plasmodium vivax malaria.
Liberia, or Guinea: a cross-sectional study rus disease received by CDC — United Malar J 2011;10:297.
from the GeoSentinel Surveillance Net- States, July 9–November 15, 2014. MMWR Copyright © 2015 Massachusetts Medical Society.
work. Ann Intern Med 2015;162:757-64. Morb Mortal Wkly Rep 2014;63:1175-9.
Lantern Slides Updated: Complete PowerPoint Slide Sets from the Clinicopathological Conferences
Any reader of the Journal who uses the Case Records of the Massachusetts General Hospital as a teaching exercise or reference
material is now eligible to receive a complete set of PowerPoint slides, including digital images, with identifying legends,
shown at the live Clinicopathological Conference (CPC) that is the basis of the Case Record. This slide set contains all of the
images from the CPC, not only those published in the Journal. Radiographic, neurologic, and cardiac studies, gross specimens,
and photomicrographs, as well as unpublished text slides, tables, and diagrams, are included. Every year 40 sets are produced,
averaging 50-60 slides per set. Each set is supplied on a compact disc and is mailed to coincide with the publication of the
Case Record.
The cost of an annual subscription is $600, or individual sets may be purchased for $50 each. Application forms for the current
subscription year, which began in January, may be obtained from the Lantern Slides Service, Department of Pathology,
Massachusetts General Hospital, Boston, MA 02114 (telephone 617-726-2974) or e-mail Pathphotoslides@partners.org.


Caso 28.2015

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Caso 28.2015

Uploaded by

Copyright:

Available Formats

The n e w e ng l a n d j o u r na l of m e dic i n e

Case Records of the Massachusetts General Hospital

Founded by Richard C. Cabot

Case 28-2015: A 32-Year-Old Man

Pr e sen tat ion of C a se

1060 n engl j med 373;11 nejm.org September 10, 2015

The New England Journal of Medicine

n engl j med 373;11 nejm.org September 10, 2015 1061

Table 1. Epidemiologic Risk Factors for Ebola Virus Disease (EVD).*

Risk Category and Associated Risk Factors Present in This Patient

1062 n engl j med 373;11 nejm.org September 10, 2015

The New England Journal of Medicine

n engl j med 373;11 nejm.org September 10, 2015 1063

1064 n engl j med 373;11 nejm.org September 10, 2015

The New England Journal of Medicine

Table 2. Laboratory Data.*

Reference Range, Second Hospital Third Hospital

n engl j med 373;11 nejm.org September 10, 2015 1065

1066 n engl j med 373;11 nejm.org September 10, 2015

The New England Journal of Medicine

Fina l Di agnosis This case was presented at Emergency Medicine Grand

n engl j med 373;11 nejm.org September 10, 2015 1067

You might also like